Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of Traditional Chinese Medicine (TCM), goserelin acetate, and bicalutamide. Goserelin acetate is a synthetic analogue of gonadotropin-releasing hormone (GnRH) that acts as an agonist at pituitary GnRH receptors, leading to downregulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in decreased testosterone production. Bicalutamide is a non-steroidal antiandrogen that blocks the action of androgens by binding to androgen receptors in prostate tissue. TCM refers to herbal or traditional formulations used adjunctively; specific compositions may vary but are generally aimed at supporting immune function and reducing side effects associated with hormonal therapy. This combination has been studied primarily for advanced prostate cancer, where it aims to improve clinical efficacy, delay disease progression, enhance immune function, reduce inflammatory markers, and mitigate adverse effects associated with long-term hormonal therapy[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tcm + goserelin acetate + bicalutamide.